HE3235 Inhibits Growth of Castration-Resistant Prostate Cancer
Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP (CRPC) for which highly effective therapies are limited. We explored the efficacy of a novel agent, HE3235, in inhibiting growth of CRPC i...
Main Authors: | Theodore D. Koreckij, Richard J. Trauger, Robert Bruce Montgomery, Tiffany E.M. Pitts, Ilsa Coleman, Holly Nguyen, Chris L. Reading, Peter S. Nelson, Robert L. Vessella, Eva Corey |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2009-11-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558609800791 |
Similar Items
-
Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
by: Hess David, et al.
Published: (2010-05-01) -
"Sleepiness" is serious in adolescence: Two surveys of 3235 Canadian students
by: Ogilvie Robert, et al.
Published: (2006-05-01) -
Therapeutic hypothermia to reduce intracranial pressure after traumatic brain injury: the Eurotherm3235 RCT
by: Peter JD Andrews, et al.
Published: (2018-08-01) -
Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone
by: Eva Corey, et al.
Published: (2013-05-01) -
Inhibition of Androgen-Independent Prostate Cancer by Estrogenic Compounds Is Associated with Increased Expression of Immune-Related Genes
by: Ilsa M. Coleman, et al.
Published: (2006-10-01)